NURSE OWNED AND OPERATED
OLIVE'S BRANCH does NOT distribute medicine
Copyright © Olive's Branch 2019
With public acceptance of cannabis as a medicine outpacing healthcare practitioner’s knowledge on the subject, it is clear there needs to be a shift. A January 2017 report, by The Health and Medicine Division (HMD) of the National Academies of Sciences, Engineering, and Medicine (the National Academies) provides a comprehensive report on the health effects of recreational and therapeutic cannabis use.
The committee considered more than 10,700 abstracts for this report.
This clearly acknowledges the medicinal value associated with cannabis and cannabinoids, hopefully bringing thoughtful consideration to the Schedule 1 status it holds.
The January 2017 report, by the, Health and Medicine Division (HMD) of the National Academies of Sciences, Engineering, and Medicine (the National Academies) published a comprehensive report on the health effects of recreational and therapeutic cannabis use. The report found that cannabis and cannabinoids are effective in the treatment of chronic pain, control of chemotherapy induced nausea & vomiting and improving spasticity associated with multiple sclerosis. The report when on to note modest support for the use of cannabinoids in improving short-term sleep disturbances. The commission highlighted key gaps in the evidence base, noting limited support for the use of cannabis or cannabinoids in the treatment of; weight gain & improved appetite associated with HIV/AIDS, Tourette syndrome, anxiety symptoms, post-traumatic stress disorder, improved outcomes for patients with traumatic brain injury or intra-cranial hemorrhage, dementia, glaucoma and depression. Researchers note that there was no statistical association between cannabis use and the incidence of lung and head & neck cancers. Although they did note limited evidence supporting a statistical association between cannabis smoking and non-seminoma-type testicular germ cell tumors.